从中证港股通医疗器械综合指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通医疗器械综合指数持仓样本的行业来看，医疗耗材占比79.10%、医疗设备占比16.57%、 体外诊断占比4.34%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证港股通综合指数调整样本时，样本随之进行 相应调整。若中证港股通综合指数样本有特殊事件发生，导致其行业归属发生变化，指数样本进行相应 调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆、停牌等情形的处理， 参照计算与维护细则处理。 本文源自：金融界 作者：行情君 金融界4月28日消息，上证指数低开震荡，中证港股通医疗器械综合指数 (港股通医疗器械，932273)报 1194.94点。 数据统计显示，中证港股通医疗器械综合指数近一个月下跌3.48%，近三个月上涨15.43%，年至今上涨 12.63%。 据了解，中证港股通行业综合指数系列在中证港股通综合 ...

（於開曼群島註冊成立之有限公司） 股份代號：6699 年度報告 目錄 | 2 | 公司資料 | | --- | --- | | 4 | 主席及首席執行官致辭 | | 8 | 業績概要 | | 11 | 管理層討論與分析 | | 21 | 非國際財務報告準則計量 | | 23 | 董事及高級管理層 | | 28 | 董事會報告 | | 61 | 企業管治報告 | | 79 | 釋義 | | 82 | 獨立核數師報告 | | 89 | 綜合全面收益表 | | 90 | 綜合財務狀況表 | | 92 | 綜合權益變動表 | | 94 | 綜合現金流量表 | | 95 | 綜合財務報表附註 | 公司資料 董事會 執行董事 胡杰章先生 （首席執行官） 黃琨先生 宋鑫先生 董莉女士 非執行董事 馮岱先生 （主席） 獨立非執行董事 韓小京先生 石子先生 周浩先生 審核委員會 周浩先生 （主席） 韓小京先生 石子先生 薪酬委員會 韓小京先生 （主席） 胡杰章先生 黃琨先生 石子先生 周浩先生 提名委員會 馮岱先生 （主席） 宋鑫先生 韓小京先生 石子先生 周浩先生 公司秘書 朱凌波先生 何詠紫女士 （自2024年7月17日起 ...

早上好 感谢大家参加时代天使的2024年全业绩发布会我是高盛的分析师ChrisThis call has simultaneous English translationand if you are English speakeryou can switch to the English channel in Zoom公司的业绩昨天已经挂网我们今天也很荣幸请到了管理层来跟我们分享一下20年的总结和对25年的展望首先我先介绍一下出席今天的管理层包括董事会主席冯黛先生 执行董事兼首席执行官和首席技术官吴捷当先生执行董事兼国际业务总裁王坤先生执行董事兼首席运营官宋鑫先生执行董事兼首席财务官董立女士高级副总裁兼董事会秘书朱铃波先生 在我们开始之前请允许我先念一段免责声明此电话会为非公开的电话会仅开放高盛和时代天使的客户参加 谢绝媒体播录如果您不是高盛或者时代天使的客户或者稍微收到加入此电话的邀请则应立即挂断电话请注意高盛里面必须能够确认此会议的所有参与者 明年的身份您可能会被从会议中移除此电话的目的不是为了分享或接收非公开或其他机密信息与会者是二级市场的参与者他们不应获得有关发行人证券或证券市场的非公开或其他机密信息 ...

Group 1 - The core viewpoint of the articles is that Times Angel has launched an innovative children's anti-caries invisible orthodontic appliance, addressing both dental health and alignment issues for children aged 6-12 [1][2] - The product combines preventive care for cavities with orthodontic functions, filling a market gap and meeting the urgent needs of parents for comprehensive oral health management [1][2] - The launch of the anti-caries appliance has received widespread acclaim, with pilot programs established in over 20 provinces and municipalities across China since the beginning of the year [1] Group 2 - According to research by Zhaoshang Consulting, the compound annual growth rate (CAGR) of children's invisible orthodontic cases in China from 2020 to 2023 exceeds 60%, indicating significant market potential [2] - Compared to the penetration rate of orthodontic treatment among children and adolescents in the United States, China's rate remains low, suggesting ample growth opportunities in the market [2] - Times Angel advocates for a "scientific early orthodontics" approach and has developed a comprehensive product matrix to meet various orthodontic needs throughout different stages of childhood [2]

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of HK$103.50, indicating an expected relative performance above the market benchmark [2][5]. Core Insights - The company achieved a total of 359,000 cases of invisible orthodontics in 2024, representing a growth of 46.7%. International cases surged to 141,000, up 326.4%, accounting for 39.1% of total cases, while domestic cases grew by 3.2% to 218,000 [3][11]. - Revenue for 2024 reached US$270 million, reflecting a year-on-year increase of 28.2%, with a gross profit margin of 62.6%. The overseas revenue was US$80.5 million, a significant increase of 290.4%, while domestic revenue slightly declined by 0.4% to US$190 million [12][13]. - The company plans to establish a manufacturing facility in Wisconsin, USA, to enhance local operational capabilities, which is expected to reduce geopolitical risks and improve brand recognition among overseas orthodontists [14]. Financial Performance and Forecast - The company forecasts revenues of US$320 million and US$390 million for 2025 and 2026, respectively, with year-on-year growth rates of 19.4% and 20.1%. The net profit attributable to shareholders is expected to be US$12.4 million and US$13.3 million for the same years, reflecting growth of 2.3% and 7.6% [5][15]. - The adjusted net profit for 2024 was US$26.86 million, with a net profit margin of 10.0%. The domestic net profit margin was stable at 19.5%, while overseas losses narrowed slightly to US$29.65 million [13][4].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [18]. Core Insights - The company achieved a revenue of $269 million in 2024, representing a year-on-year growth of 28.2%, and a net profit attributable to shareholders of $12 million, up 60.9% [2][4]. - The number of cases handled reached 359,400, marking a significant increase of 46.7% [2][4]. - The international expansion strategy is proving effective, with overseas case numbers soaring by 326.4% to 140,700, accounting for 39.1% of total cases, and overseas revenue increasing by 290.4% to $8.1 million, representing 30% of total revenue [4][5]. Financial Performance - The domestic market showed stable growth, with 218,700 cases (+3.2%) and revenue of $188 million (-0.4%), while the adjusted net profit remained stable at $37 million (+0.1%) [5]. - The overall gross margin improved to 62.6%, with a net margin of 3.7% and an adjusted net margin of 10.0% [6]. - The company is expected to see revenue growth projections for 2025-2027 at RMB 2.35 billion, RMB 2.72 billion, and RMB 3.22 billion respectively, with net profits projected at RMB 151 million, RMB 282 million, and RMB 385 million [6][7].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% within the next six months [20]. Core Insights - The company achieved a revenue of $269 million in 2024, representing a year-on-year growth of 28.2%, and a net profit of $12 million, which is a 60.9% increase [2][4]. - The number of cases handled reached 359,400, marking a significant increase of 46.7% [2][4]. - The international expansion strategy is proving effective, with overseas case numbers soaring by 326.4% to 140,700, accounting for 39.1% of total cases [4][5]. - The overseas revenue reached $8.1 million, a remarkable increase of 290.4%, contributing to 30% of total revenue [4][5]. Financial Performance - The overall gross margin for 2024 was 62.6%, with a net profit margin of 3.7%, both showing slight improvements year-on-year [6]. - The adjusted net profit margin was 10.0%, reflecting a decrease of 2.1 percentage points [6]. - The company’s domestic business maintained a steady growth, with domestic case numbers increasing by 3.2% to 218,700, while domestic revenue slightly declined by 0.4% to $188 million [5][6]. Future Projections - Revenue forecasts for 2025-2027 have been revised upwards, with expected revenues of 2.35 billion, 2.72 billion, and 3.22 billion RMB respectively [6]. - The projected net profits for the same period are 151 million, 282 million, and 385 million RMB, with corresponding P/E ratios of 63, 34, and 25 [6][7].

Summary of Angelalign Technology Inc Conference Call Company Overview - **Company**: Angelalign Technology Inc (6699.HK) - **Industry**: China Healthcare - **Current Stock Price**: HK$63.85 (as of March 21, 2025) - **Price Target**: Raised from HK$72.00 to HK$74.00 [2][4] Key Financial Updates - **Revenue Forecasts**: Increased by 5% for 2025, 7% for 2026, and 8% for 2027, driven by higher overseas growth [3][4] - **EPS Estimates**: Adjusted to -5% for 2025, +9% for 2026, and +12% for 2027 on a constant currency basis [3] - **GPM and OPM**: Lowered assumptions due to longer ramp-up times for new facilities in the US and Brazil [3] - **DCF Model**: Extended to 2035 with WACC reduced from 13% to 11% due to lower supply chain risks [4] Market Position and Growth Potential - **Market Share**: Angelalign holds over 40% case volume share in the clear aligner market, surpassing Invisalign since 2021 [11] - **Overseas Expansion**: Initiated in 2023-24, with significant growth potential from low existing market share [11] - **Supply Chain Diversification**: Initiatives in place to mitigate tariff risks, although breakeven may be delayed [11] Investment Thesis - **Valuation**: Despite high near-term P/E ratios reflecting expected overseas losses in 2025-26, the valuation remains attractive [12] - **Revenue Growth**: Anticipated strong near-term revenue growth due to industry demand recovery and market share gains in China [10] - **Risk Factors**: Potential risks include market share loss, rising competition, and delays in overseas ramp-up [23] Earnings Inputs - **China Case Shipment Volume**: Expected to grow from 218,700 in 2024 to 248,963.6 in 2027 [18] - **Overseas Case Shipment Volume**: Projected to increase from 140,700 in 2024 to 370,392.8 in 2027 [18] - **Selling Cost Ratio**: Expected to decrease from 39.1% in 2024 to 30.5% in 2027 [18] Consensus and Ratings - **Stock Rating**: Equal-weight [5] - **Industry View**: Attractive [5] - **Consensus Price Target Distribution**: Ranges from HK$64.07 to HK$103.38 [9] Conclusion Angelalign Technology Inc is positioned for growth with a strong market share in the clear aligner sector and significant overseas expansion potential. Despite some risks associated with competition and operational ramp-up, the company's financial outlook remains positive with revised revenue forecasts and a slightly increased price target.

Investment Rating - The report maintains a "Buy" rating for the company, anticipating a price increase of over 15% within the next 6-12 months [4][13]. Core Viewpoints - The company achieved a revenue of $26.9 million in 2024, reflecting a year-on-year growth of 28%, while the adjusted net profit was $26.9 million, up 3% [1]. - The international market outside of China has become a significant growth driver, with a 326.4% increase in invisible orthodontic cases and a revenue increase of 290.4% in 2024 [2]. - The company is strategically expanding its sales team in the domestic market, achieving a 3.2% increase in cases, although revenue in China slightly declined by 0.4% [2]. - The gross margin improved to 62.6%, with sales and marketing expenses rising by 49.9% due to international expansion efforts [3]. - The company is expected to continue its growth trajectory, with projected net profits of $1.06 billion, $1.28 billion, and $1.54 billion for 2024-2026, representing growth rates of 21%, 21%, and 20% respectively [4]. Summary by Sections Performance Review - In 2024, the company reported a revenue of $26.9 million, a 28% increase year-on-year, and an adjusted net profit of $26.9 million, up 3% [1]. Operational Analysis - The total number of cases reached 359,400 in 2024, a 47% increase year-on-year, with significant growth in international markets [2]. - The company recorded 140,700 cases outside of China, marking a 326.4% increase, and generated $80.5 million in revenue from these markets, a 290.4% increase [2]. - In the domestic market, the company achieved 218,700 cases, a 3.2% increase, but revenue slightly decreased by 0.4% to $188.2 million [2]. Profitability and Expenses - The gross margin for 2024 was 62.6%, an increase of 0.2 percentage points year-on-year [3]. - Sales and marketing expenses rose to approximately $105 million, a 49.9% increase, primarily due to the expansion of international operations [3]. Profit Forecast and Valuation - The company is projected to achieve net profits of $1.06 billion, $1.28 billion, and $1.54 billion for 2024-2026, with corresponding EPS of 0.62, 0.75, and 0.90 [4]. - The current price-to-earnings ratio is projected to be 114, 95, and 79 for the years 2024-2026 [4].

RSU Grant and Vesting - The company announced the grant of 72,975 restricted stock units (RSUs) to 50 employees, equivalent to 72,975 shares of common stock, as part of its post-IPO restricted stock unit plan[3]. - The RSUs will vest in four tranches: 30% on September 30, 2025, 30% on September 30, 2026, 20% on September 30, 2027, and 20% on September 30, 2028[9]. - The total number of shares available for future grants under the post-IPO restricted stock unit plan is capped at 3,381,955 shares, with 1,478,931 shares available for future grants as of the announcement date[15]. - The RSUs granted do not have any performance targets attached to them[11]. - The purchase price for the shares on the RSU grant date is set at HKD 63.85 per share[9]. - The vesting schedule allows for some RSUs to have a vesting period of less than 12 months, subject to board discretion[9]. - The company has established mechanisms to ensure that unvested RSUs will be forfeited under certain conditions, such as termination of employment or misconduct[12]. Employee Motivation and Alignment - The company aims to recognize the contributions of RSU recipients and align their interests with those of shareholders to maximize employee motivation[14]. - The board believes that granting RSUs is an important measure to incentivize recipients to deliver higher returns for the company[14]. Financial Performance - The company's gross profit increased by 28.7% from approximately $130.7 million for the year ended December 31, 2023, to approximately $168.2 million for the year ended December 31, 2024[16]. - The gross profit margin for the year ended December 31, 2024, was approximately 62.6%[16].